首页> 外文期刊>ERJ Open Research >Functional characterisation of bone marrow-derived mesenchymal stromal cells from COPD patients
【24h】

Functional characterisation of bone marrow-derived mesenchymal stromal cells from COPD patients

机译:COPD患者骨髓间充质基质细胞的功能表征

获取原文
       

摘要

Autologous bone marrow-derived mesenchymal stromal cells (BM-MSCs) are evaluated for clinical use in chronic obstructive pulmonary disease (COPD) patients, but it is unclear whether COPD affects BM-MSCs.To investigate this, BM-MSCs from nine COPD patients and nine non-COPD age-matched controls were compared with regard to immunophenotype, growth and differentiation potential, and migration capacity. Other functional assays included the response to pro-inflammatory stimuli and inducers of the nuclear factor (erythroid derived 2)-like 2 antioxidant response element (Nrf2-ARE) pathway, and effects on NCI-H292 airway epithelial cells.No significant differences were observed in terms of morphology, proliferation and migration, except for increased adipocyte differentiation potential in the COPD group. Both groups were comparable regarding mRNA expression of growth factors and inflammatory mediators, and in their potential to induce mRNA expression of epidermal growth factor receptor ligands in NCI-H292 airway epithelial cells. MSCs from COPD patients secreted more interleukin-6 in response to pro-inflammatory stimuli. Activation of the Nrf2-ARE pathway resulted in a comparable induction of mRNA expression of four target genes, but the expression of the NAD(P)H:quinone oxidoreductase 1 gene NQO1 was lower in MSCs from COPD patients.The observation that MSCs from COPD patients are phenotypically and functionally comparable to those from non-COPD controls implies that autologous MSCs can be considered for use in the setting of clinical trials as a treatment for COPD.Phenotype and functional analysis of BM-MSCs from COPD patients supports their use in autologous MSC treatment http://ow.ly/TRtX3008t6c
机译:对自体骨髓源间充质基质细胞(BM-MSC)在慢性阻塞性肺疾病(COPD)患者中的临床应用进行了评估,但尚不清楚COPD是否会影响BM-MSC。比较了9个非COPD年龄匹配的对照的免疫表型,生长和分化潜能以及迁移能力。其他功能性检测包括对促炎反应的刺激和核因子(类胡萝卜素衍生2)样2抗氧化剂反应元件(Nrf2-ARE)途径的诱导剂,以及对NCI-H292气道上皮细胞的影响。在形态,增殖和迁移方面,COPD组的脂肪细胞分化潜能增加。两组在生长因子和炎性介质的mRNA表达以及在NCI-H292气道上皮细胞中诱导表皮生长因子受体配体mRNA表达的潜力方面具有可比性。来自COPD患者的MSC响应促炎性刺激分泌更多的白介素6。 Nrf2-ARE途径的激活导致四个靶基因的mRNA表达具有可比的诱导作用,但COPD患者的MSC中NAD(P)H:醌氧化还原酶1基因NQO1的表达较低。患者的表型和功能与非COPD对照者相似,这意味着可以考虑将自体MSC用于临床试验作为COPD的治疗。COPD患者的BM-MSC的表型和功能分析支持其用于自体MSC处理

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号